Relay Therapeutics
Tracked across 2 events · 13 articles · First seen Apr 27, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Relay Therapeutics is advancing its drug zovegalisib into Phase 3 development for metastatic breast cancer, which could significantly boost its market position and revenue if approved.
Apr 27, 2026 · 6 articles
Regulatory
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., announced on September 22, 2026 that the U.S. United States — Food and Drug Administration granted conditional acceptance of LYRFIGTU as the brand name for…
Impact: Relay Therapeutics is the licensor of lirafugratinib to Elevar Therapeutics for worldwide commercialization. Progress toward approval could yield milestone or royalty value for Relay, though it is a secondary beneficiary in this event.
Sep 22, 2026 · 7 articles
40
Elevar Therapeutics licensed lirafugratinib Relay TherapeuticsFDA Conditional Acceptance...
ERGEN INTELLIGENCE
Track Relay Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard